Liver metastases

What is are liver metastases?

Liver metastases are secondary tumors that develop when cancer cells break away from a primary tumor elsewhere in the body and spread to the liver. Unlike primary liver cancer, these cells originate in a different organ and travel through the bloodstream.

The liver's massive blood supply makes it uniquely vulnerable to capturing floating cancer cells, making metastases 20 times more common than cancers that start in the liver itself.

The primary cancers most commonly responsible include:

• Colorectal cancer: the most frequent source, affecting roughly 50% of patients. Because blood from the gut drains directly into the liver, it creates a direct pathway for cells to take root.

• Breast cancer: frequently spreads to the liver, particularly in hormone receptor-positive and HER2-positive subtypes.

• Lung cancer: both non-small cell and small cell types commonly involve the liver in advanced stages.

• Pancreatic cancer: has an exceptionally high rate of early liver spread due to its aggressive nature and close vascular connection.

• Gastric and oesophageal cancer: readily travel to the liver via the shared digestive blood highway.

• Neuroendocrine tumours: often spread heavily to the liver, sometimes creating secondary tumors that grow larger than the original tumor itself.

• Renal cell carcinoma: spreads from the kidneys to the liver through the bloodstream.

• Melanoma: this aggressive skin cancer can spread to the liver as part of its systemic movement through the body.

Symptoms of liver metastases

Liver metastases are frequently asymptomatic in their early stages, particularly when few in number and small in size. When symptoms occur they reflect progressive liver involvement and the consequences of hepatic dysfunction:

• Right upper abdominal discomfort, fullness, or pain from liver capsule distension as metastases enlarge

• Unexplained fatigue and weakness from systemic malignancy and progressive liver dysfunction

• Unexplained weight loss and loss of appetite

• Jaundice from biliary obstruction by metastases near the hilum or from extensive parenchymal replacement

• Ascites from portal hypertension in advanced hepatic involvement

• Fever from tumour necrosis or associated infection

• Symptoms of the primary cancer site alongside hepatic symptoms

In people with a known primary cancer, new upper abdominal symptoms or deteriorating liver function tests should always prompt urgent hepatic imaging.

What causes liver metastases?

Liver metastases develop when cancer cells from a primary tumor enter the bloodstream or lymphatic system and establish secondary deposits in the liver. Contributing factors include:

• Portal venous drainage the direct blood flow from the gastrointestinal tract to the liver through the portal vein explains the high rate of liver metastasis from colorectal, gastric, and pancreatic cancers

• Hepatic arterial supply systemic cancers including breast, lung, and melanoma reach the liver through the hepatic artery

• Tumour biology certain cancers have a particular affinity for the hepatic microenvironment, with specific molecular signals promoting adhesion and growth of circulating tumour cells in liver tissue

• Angiogenesis liver metastases require the development of a new blood supply to grow beyond a microscopic size, with the vascular biology of specific metastatic subtypes determining their imaging appearance and treatment response

• Disease stage the likelihood of liver metastasis increases significantly with advancing primary tumour stage, lymph node involvement, and the presence of other distant metastases

How are liver metastases detected?

Liver metastases are detected through abdominal imaging, with blood tests providing functional liver assessment and relevant tumour markers.

Abdominal MRI Elfcare’s full body MRI is among the most sensitive imaging available for detecting liver metastases, picking up lesions as small as a few millimetres and distinguishing them from harmless growths like cysts. How these lesions respond to contrast dye, brightening intensely like breast or kidney metastases, or appearing dark with a bright rim like colon or pancreatic metastases, can even help point toward an unknown primary cancer. By pinpointing the number of lesions and how close they sit to major blood vessels, the MRI gives the medical team a precise map to work out whether they can be safely removed surgically.

Blood tests assess liver function and provide tumour marker context relevant to the most common primary cancers causing liver metastases. Relevant markers in Elfcare's panel include:

• ALT, AST, GGT, ALP, and bilirubin liver function profile, assessing the degree of hepatic dysfunction from metastatic involvement. ALP is characteristically elevated in liver metastases, often disproportionately to other liver enzymes

• Albumin low albumin reflects significant liver synthetic dysfunction from extensive metastatic replacement or advanced systemic malignancy

• CRP elevated systemic inflammation reflecting active malignancy and hepatic involvement

• Total PSA in men, elevated PSA alongside liver lesions raises concern for prostate cancer metastases

• Hemoglobin and full blood count anaemia of chronic disease is common in metastatic cancer and provides general systemic context

• HbA1c and glucose metabolic context relevant to the overall clinical picture

Why early detection matters

The treatment options available for liver metastases depend critically on their number, size, distribution, and the degree of hepatic involvement at the time of detection. Colorectal cancer liver metastases confined to one lobe, identified when few and small, may be resectable with curative intent, achieving five-year survival rates of 30 to 50%. The same metastases identified when bilateral, multiple, and large are unresectable and managed with palliative systemic chemotherapy. Neuroendocrine tumour liver metastases identified early can be treated with surgical debulking, ablation, or peptide receptor radionuclide therapy that significantly extends survival. For any primary cancer, the identification of liver metastases before extensive hepatic replacement has occurred expands the range of systemic and locoregional treatment options available and provides the best possible starting point for treatment planning.

How Elfcare can help

Elfcare's full body MRI images the liver with the sensitivity needed to identify metastases at their smallest detectable size, before they have caused symptoms or significant hepatic dysfunction. For people with a known cancer history, this represents the most direct surveillance tool available for detecting hepatic spread at the earliest possible stage. For people without a known cancer history in whom liver lesions are found incidentally, MRI characterisation of the lesion pattern, enhancement characteristics, and associated abdominal findings often provides the first indication of an occult primary cancer requiring urgent investigation.

Our blood panel covers liver function, ALP, albumin, CRP, and PSA, providing the functional and systemic context alongside the structural MRI findings.

If our MRI or blood tests identify liver metastases or findings consistent with hepatic malignancy, we take care of further diagnostics or refer you to the appropriate specialist urgently.